John focuses his corporate and transactional practice on the health care and life sciences industry, as well as other highly regulated sectors. He represents public and private companies in acquisitions, investments, debt financings, joint ventures, commercial contracts, and private placements. John also advises companies in these sectors on strategic mergers and acquisitions, and public exit strategies. He also advises private funds on formation, structure, and capital allocation in the health care, life sciences, and digital medicine sectors. John has led several high-profile transactions in the U.S. health care arena and routinely counsels portfolio companies, venture capital funds, and private equity funds on transactional, regulatory, and licensing matters. His clients include biopharma companies, biotech companies, specialty pharmacy suppliers, GPOs, specialty-care providers, and the full range of institutional clinical (Part A), and primary and specialty (Part B) service providers. John counsels clients in transactions, and compliance with Medicare, Medicaid, and U.S. Department of Justice initiatives, including CID responses. In addition to transactional and regulatory work, John serves as outside general counsel to innovative entities, and has experience representing investment banks and private funds in technology and digital health care deals.
John is widely regarded for his innovative, hands-on approach. Clients describe him as a trusted partner who blends legal experience with a deep understanding of the health care market, offering tailored, proactive solutions. His exceptional insight and strategic guidance have earned him significant recognition, with clients noting that he consistently delivers high-caliber, customized experiences that position their companies for sustainable success in an increasingly regulated environment. John’s ability to work seamlessly with his colleagues has solidified his reputation for leading dynamic, cohesive teams that consistently exceed expectations.